FDA Expands Label for CVRx Barostim System in HF

 The Barostim neuromodulation system is now indicated in NYHA class III or class II HF despite guideline-directed medical therapies, with LVEF ≤ 35% and NT-proBNP < 1600 pg/mL.
Medscape Medical News

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart